

Resource Summary Report

Generated by [RRID](#) on Sep 1, 2026

PEO4

RRID:CVCL_2690

Type: Cell Line

Proper Citation

RRID:CVCL_2690

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2690

Proper Citation: RRID:CVCL_2690

Description: Cell line PEO4 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: BRCA2 syndrome

Defining Citation: [PMID:1348364](#), [PMID:3167863](#), [PMID:3583449](#), [PMID:8824553](#), [PMID:9041185](#), [PMID:19654294](#), [PMID:20581869](#), [PMID:22183581](#), [PMID:22328975](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:25230021](#), [PMID:25960936](#), [PMID:27235858](#), [PMID:27561551](#), [PMID:28273451](#), [PMID:30971826](#), [PMID:35028612](#)

Comments: Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: PEO4

Synonyms: PE04, PEO-4

Cross References: BTO:BTO_0005797, EFO:EFO_0005448, ArrayExpress:E-MTAB-691, BioGRID_ORCS_Cell_line:993, cancercellines:CVCL_2690, CancerTools:151673, Cell_Model_Passport:SIDM00471, Cosmic:1709261, DepMap:ACH-001632, ECACC:10032309, GEO:GSM185147, GEO:GSM185148, GEO:GSM459657, GEO:GSM459854, GEO:GSM743510, GEO:GSM851939, GEO:GSM1340590, GEO:GSM2475002, GEO:GSM4973222, GEO:GSM4973228, GEO:GSM4973234,

GEO:GSM4973240, GEO:GSM4973246, GEO:GSM4973252, GEO:GSM4973258, GEO:GSM4973264, GEO:GSM4973270, PRIDE:PXD003668, PRIDE:PXD020764, Progenetix:CVCL_2690, Wikidata:Q54947168, Ximbio:151673

ID: CVCL_2690

Record Creation Time: 20220427T221430+0000

Record Last Update: 20260829T235622+0000

Ratings and Alerts

No rating or validation information has been found for PEO4.

No alerts have been found for PEO4.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zeng Z, et al. (2026) Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer. British journal of cancer, 134(12), 1830.

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. Molecular cancer therapeutics.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. Advanced biology, 10(3), e00404.

Szmyd R, et al. (2025) Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage. Nature cell biology, 27(1), 59.

Kenny HA, et al. (2025) Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. Molecular cancer therapeutics, 24(8), 1252.

Lake RJ, et al. (2025) Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer. Cancer research communications, 5(10), 1796.

Xu H, et al. (2024) CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience, 27(7), 109978.

Nie H, et al. (2024) Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade. *Nature communications*, 15(1), 2853.

Xu Y, et al. (2023) Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. *Cell reports*, 42(10), 113307.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. *Nature communications*, 14(1), 3742.

Liu H, et al. (2022) KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. *Cancer immunology research*, 10(8), 1028.

Lin J, et al. (2021) The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity. *Cancer immunology research*, 9(12), 1413.

Patel M, et al. (2021) The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer. *Cancer research*, 81(15), 3985.

Huang D, et al. (2021) Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. *Cell reports. Medicine*, 2(12), 100471.

Yan P, et al. (2020) Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. *Cell reports*, 31(13), 107840.

Naskou J, et al. (2020) EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. *Molecular cancer research : MCR*, 18(2), 278.

Kim JJ, et al. (2020) PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells. *Molecular cell*, 80(2), 327.